Diadenosines as FHIT‐ness instructors

FHIT is a tumor suppressor gene that is frequently inactivated in human cancer. Although the Fhit protein is known to hydrolyze diadenosine triphosphate (Ap3A), this hydrolase activity is not required for Fhit‐mediated oncosuppression. Indeed, the molecular mechanisms and the regulatory elements of Fhit oncosuppression are largely unknown. Here, we review physiological and pathological aspects of Fhit in the context of the ApnA family of signaling molecules, as well as the involvement of Fhit in apoptosis and the cell cycle in cancer models. We also discuss recent findings of novel Fhit interactions that may lead to new hypotheses about biochemical mechanisms underlying the oncosuppressor activity of this gene. J. Cell. Physiol. 208: 274–281, 2006. © 2006 Wiley‐Liss, Inc.

[1]  G. Sozzi,et al.  Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer. , 2006, Neoplasia.

[2]  K. Huebner,et al.  Fhit and CHK1 have opposing effects on homologous recombination repair. , 2005, Cancer research.

[3]  Y. Pekarsky,et al.  Lung cancer susceptibility in Fhit-deficient mice is increased by Vhl haploinsufficiency. , 2005, Cancer research.

[4]  L. D. Barnes,et al.  Phosphorylation of the human Fhit tumor suppressor on tyrosine 114 in Escherichia coli and unexpected steady state kinetics of the phosphorylated forms. , 2005, Biochemistry.

[5]  K. Huebner,et al.  Involvement of the Fhit gene in the ionizing radiation‐activated ATR/CHK1 pathway , 2005, Journal of cellular physiology.

[6]  G. Giaccone,et al.  The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression , 2004, Oncogene.

[7]  C. Croce,et al.  Inactivation of the FHIT Gene Favors Bladder Cancer Development , 2004, Clinical Cancer Research.

[8]  G. Sozzi,et al.  Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line , 2004, Oncogene.

[9]  C. Croce,et al.  Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant , 2004, British Journal of Cancer.

[10]  C. Croce,et al.  Development of spontaneous tumours and intestinal lesions in Fhit gene knockout mice , 2004, British Journal of Cancer.

[11]  J. Minna,et al.  Synergistic Tumor Suppression by Coexpression of FHIT and p53 Coincides with FHIT-Mediated MDM2 Inactivation and p53 Stabilization in Human Non-Small Cell Lung Cancer Cells , 2004, Cancer Research.

[12]  T. Pawełczyk,et al.  Ubc9-induced inhibition of diadenosine triphosphate hydrolase activity of the putative tumor suppressor protein Fhit. , 2004, Archives of biochemistry and biophysics.

[13]  L. D. Barnes,et al.  Fhit is a physiological target of the protein kinase Src. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  C. Croce,et al.  Cancer prevention and therapy in a preclinical mouse model: impact of FHIT viruses. , 2004, Current gene therapy.

[15]  T. Pawełczyk,et al.  Distribution of Fhit protein in rat tissues and its intracellular localization , 2001, Molecular and Cellular Biochemistry.

[16]  G. Gabriëls,et al.  Vasoactivity of diadenosine polyphosphates in human small renal resistance arteries. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  A. Dejean,et al.  Nuclear and unclear functions of SUMO , 2003, Nature Reviews Molecular Cell Biology.

[18]  K. Sano,et al.  Hydrolysis of diadenosine polyphosphates by nucleotide pyrophosphatases/phosphodiesterases. , 2003, European journal of biochemistry.

[19]  B M Stavrou Diadenosine polyphosphates: postulated mechanisms mediating the cardiac effects. , 2003, Current medicinal chemistry. Cardiovascular and hematological agents.

[20]  A. Vartanian Gelsolin and plasminogen activator inhibitor-1 are Ap3A-binding proteins. , 2003, The Italian journal of biochemistry.

[21]  C. Croce,et al.  Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Pintor,et al.  Presence of Diadenosine Polyphosphates in the Aqueous Humor: Their Effect on Intraocular Pressure , 2003, Journal of Pharmacology and Experimental Therapeutics.

[23]  Y. Pekarsky,et al.  FHIT: from gene discovery to cancer treatment and prevention. , 2002, The Lancet. Oncology.

[24]  A. Sillero,et al.  Dinucleoside polyphosphates stimulate the primer independent synthesis of poly(A) catalyzed by yeast poly(A) polymerase. , 2002, European journal of biochemistry.

[25]  Ann Janssen,et al.  Vasoactivity of diadenosine polyphosphates in human small mesenteric resistance arteries. , 2002, The Journal of pharmacology and experimental therapeutics.

[26]  Charles Brenner,et al.  Hint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases. , 2002, Biochemistry.

[27]  C. Croce,et al.  Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  C. Croce,et al.  Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies. , 2001, JAMA.

[29]  D. Roymans,et al.  P2YAC−‐receptor agonists enhance the proliferation of rat C6 glioma cells through activation of the p42/44 mitogen‐activated protein kinase , 2001 .

[30]  C. Croce,et al.  The tumor spectrum in FHIT-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Sheridan,et al.  Contribution of nitric oxide and prostanoids to the cardiac electrophysiological and coronary vasomotor effects of diadenosine polyphosphates. , 2001, The Journal of pharmacology and experimental therapeutics.

[32]  E. Rosato,et al.  Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. , 2001, Cancer research.

[33]  C. Croce,et al.  FHIT gene therapy prevents tumor development in Fhit-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  C. Croce,et al.  Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. , 2001, Cancer research.

[35]  D. Roymans,et al.  P2Y(AC)(-)-receptor agonists enhance the proliferation of rat C6 glioma cells through activation of the p42/44 mitogen-activated protein kinase. , 2001, British journal of pharmacology.

[36]  J. Pintor,et al.  Presence of diadenosine polyphosphates in human tears , 2001, Pflügers Archiv.

[37]  A. McLennan Dinucleoside polyphosphates-friend or foe? , 2000, Pharmacology & therapeutics.

[38]  J. Pintor,et al.  Diadenosine polyphosphate receptors. from rat and guinea-pig brain to human nervous system. , 2000, Pharmacology & therapeutics.

[39]  A. Guranowski Specific and nonspecific enzymes involved in the catabolism of mononucleoside and dinucleoside polyphosphates. , 2000, Pharmacology & therapeutics.

[40]  K. Huebner,et al.  Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression. , 2000, Cancer research.

[41]  D. Notterman,et al.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. , 2000, Genes & development.

[42]  C. Brenner,et al.  Fhit-nucleotide Specificity Probed with Novel Fluorescent and Fluorogenic Substrates* , 2000, The Journal of Biological Chemistry.

[43]  M. Paterson,et al.  Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9. , 2000, The Biochemical journal.

[44]  A. Guranowski,et al.  Selective degradation of 2'-adenylated diadenosine tri- and tetraphosphates, Ap(3)A and Ap(4)A, by two specific human dinucleoside polyphosphate hydrolases. , 2000, Archives of biochemistry and biophysics.

[45]  C. Croce,et al.  Muir-Torre-like syndrome in Fhit-deficient mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Y. Pekarsky,et al.  FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. , 1999, Cancer research.

[47]  C. Croce,et al.  The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Minna,et al.  Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. , 1999, Cancer research.

[49]  C. Croce,et al.  Loss of FHIT function in lung cancer and preinvasive bronchial lesions. , 1998, Cancer research.

[50]  B. Soria,et al.  Intracellular diadenosine polyphosphates: a novel second messenger in stimulus‐secretion coupling , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[51]  D. Beer,et al.  The murine Fhit gene is highly similar to its human orthologue and maps to a common fragile site region. , 1998, Cancer research.

[52]  Y. Pekarsky,et al.  Nitrilase and Fhit homologs are encoded as fusion proteins in Drosophila melanogaster and Caenorhabditis elegans. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[53]  L. D. Barnes,et al.  Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[54]  A. Wolfson,et al.  Diadenosine oligophosphates (Ap n A), a novel class of signalling molecules? , 1998, FEBS letters.

[55]  P. Plateau,et al.  Control of 5′,5′-Dinucleoside Triphosphate Catabolism by APH1, a Saccharomyces cerevisiaeAnalog of Human FHIT , 1998, Journal of bacteriology.

[56]  L. D. Barnes,et al.  Replacement of Fhit in cancer cells suppresses tumorigenicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[57]  L. D. Barnes,et al.  Purification and crystallization of complexes modeling the active state of the fragile histidine triad protein. , 1997, Protein engineering.

[58]  A. Vartanian,et al.  Opposite effects of cell differentiation and apoptosis on Ap3A/Ap4A ratio in human cell cultures , 1997, FEBS letters.

[59]  A. Terzic,et al.  Intracellular diadenosine polyphosphates: a novel family of inhibitory ligands of the ATP-sensitive K+ channel. , 1997, Biochemical pharmacology.

[60]  L. D. Barnes,et al.  Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5"'-P1,P3-triphosphate hydrolase. , 1996, Biochemistry.

[61]  Motonao Nakamura,et al.  Functional coupling of adenosine A2a receptor to inhibition of the mitogen-activated protein kinase cascade in Chinese hamster ovary cells. , 1996, The Biochemical journal.

[62]  S. Edwards,et al.  The diadenosine polyphosphates Ap3A and Ap4A and adenosine triphosphate interact with granulocyte-macrophage colony-stimulating factor to delay neutrophil apoptosis: implications for neutrophil: platelet interactions during inflammation. , 1996, Blood.

[63]  C. Croce,et al.  The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma–Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract Cancers , 1996, Cell.

[64]  J. Vishwanatha,et al.  Uracil DNA-glycosylase/glyceraldehyde-3-phosphate dehydrogenase is an Ap4A binding protein. , 1995, Biochemistry.

[65]  M. Maa,et al.  Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[66]  J. Vishwanatha,et al.  Characterization of the HeLa cell DNA polymerase alpha-associated Ap4A binding protein by photoaffinity labeling. , 1994, Biochemistry.

[67]  T. Merkulova,et al.  P1, P3‐bis(5′‐adenosyl)triphosphate (Ap3A) as a substrate and a product of mammalian tryptophanyl‐tRNA synthetase , 1994, FEBS letters.

[68]  D. Volkin,et al.  Interaction of nucleotides with acidic fibroblast growth factor (FGF-1). , 1994, Biochemistry.

[69]  J. Estrela,et al.  Inhibition of cancer growth and selective glutathione depletion in Ehrlich tumour cells in vivo by extracellular ATP. , 1994, The Biochemical journal.

[70]  A. Wolfson,et al.  Aminoacyl-tRNA synthetases from higher eukaryotes. , 1994, Progress in nucleic acid research and molecular biology.

[71]  P. Plateau,et al.  Dinucleoside oligophosphates in micro-organisms. , 1994, Advances in microbial physiology.

[72]  E. Fuge,et al.  AppppA-binding protein E89 is the Escherichia coli heat shock protein ClpB , 1993, Journal of bacteriology.

[73]  J. Jackson,et al.  Inhibition of bovine retinal microvascular pericyte proliferation in vitro by adenosine. , 1992, The American journal of physiology.

[74]  P. Plateau,et al.  In vivo synthesis of adenylylated bis(5'-nucleosidyl) tetraphosphates (Ap4N) by Escherichia coli aminoacyl-tRNA synthetases. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[75]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[76]  P. Plateau,et al.  Zinc-dependent synthesis of various dinucleoside 5',5' ' '-P1,P3-Tri- or 5'',5' ' '-P1,P4-tetraphosphates by Escherichia coli lysyl-tRNA synthetase. , 1982, Biochemistry.

[77]  E. Holler,et al.  Mechanism of synthesis of adenosine(5')tetraphospho(5')adenosine (AppppA) by aminoacyl-tRNA synthetases. , 1982, European journal of biochemistry.

[78]  M. Stephenson,et al.  Enzymatic synthesis of diadenosine tetraphosphate and diadenosine triphosphate with a purified lysyl-sRNA synthetase. , 1966, Biochemical and biophysical research communications.